Sumitomo Pharma Co., Ltd. DNPUF OTC · Healthcare · Japan
$10.50 -11.84% -$1.41
Summary
53 / 100 · Bulios Score
What speaks for it
- You pay 16.2 JPY for 1 JPY of yearly profit, little for its sector.
- Out of every 100 JPY of revenue, 14 JPY is left as free cash.
What to watch
- Revenue fell by 6.4% a year over the last 3 years.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBy our assumptions the price matches the value of the business: the two differ by less than 10 %.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 16.2 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue fell by 2.4% a year over 5 years. Over the last 3 years it fell by 6.4% a year.
Growth in detailDoes it make money?
Very wellWhere 100 JPY of revenue goes
- Cost of sales 47 JPY
- Research and development 10 JPY
- Sales and administration 33 JPY
- Taxes and other 0.3 JPY
- Net profit 9.4 JPY
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 9.9 JPY
Out of every 100 JPY of revenue, 9.4 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 1
- Sell 0
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.